healthy humans
Conditions
Interventions
Oral ingestion of the placebo control food once daily for 12 weeks
Oral ingestion of the test food(HB-h008) once daily for 12 weeks
Sponsors
Miura Clinic, Medical Corporation Kanonkai
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) 20<=Age<60 of healty men and women (2) 23<=BMI<30
Exclusion criteria
Exclusion criteria: (1) Subjects with diabetes, liver disease, kidney disease, gastrointestinal disease, peripheral vascular disease, or medical history for severe diseases (2) Subjects who indicate disorder of heart and lung function (3) Subjects who indicate abnormal parameter in liver or kidney function (4) Subjects who had a gastrointestinal surgery (5) Subjects with a disease under treatment now (6) Subjects with drug or food allergy (7) Subjects who play high intensity sports or are on a diet (8) Subjects who have a weight change: 2 kg or more when comparing to 1 month prior to the start of the trial (9) Subjects who are taking medication or functional foods which might affect the results of this study, such as medicine, quasi drug and health foods (10) Subject who consume exscessive alcohol (11) Subject who has been pregnant or subject who have a plan to become pregnant or breast feed during the study period (12) Subjects who is participating in the other study or plannning to participate during the study period (13) Subjects who isdeemed unsuitable by the principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Body fat area(Visceral fat area, Subcutaneous fat area, Total fat area) Measuring: at 0 week, 6 weeks and 12 weeks after ingestion | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight, BMI, Waist circumference, Hip circumference, Blood glucose, Insulin, Glycoalbumin Measuring: at 0 week, 6 weeks and 12 weeks after ingestion | — |
Countries
Japan
Contacts
Public ContactMakoto Terashima
Oneness support Co., Ltd. Clinical trial Division
Outcome results
None listed